Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
oleh: Khadega A. Abuelgasim, Raed Al Shammari, Saeed Alshieban, Bader Alahmari, Mohsen Alzahrani, Ayman Alhejazi, Ahmed Alaskar, Moussab Damlaj
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2021-01-01 |
Deskripsi
The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases. The 3-year PFS was 75.1% for CD20+and 70% for CD20− (p = 0.36). The 3-year PFS was 84.7% for the rituximab group and 67.8% for the no rituximab group (p = 0.23). Only constitutional symptoms and positive interim PET/CT were significantly associated with worse outcome, HR 3.2 (1.14–9.01; p = 0.028) and 4.3 (2.27–8.1; p < 0.0001), respectively. Neither CD20 expression nor rituximab use significantly impacted outcome.